Bill
HR 5197
The Protect Beneficiaries from Middlemen Act ensures patients receive full healthcare benefits by promoting transparency and reducing middlemen's influence on costs.
Bill Number: HR 5197
Title: Protect Beneficiaries from Middlemen Act
Status: Introduced in House
Introduced Date: September 08, 2025
Classification: Bill
The Protect Beneficiaries from Middlemen Act aims to enhance transparency and accountability in the healthcare system by addressing the role of intermediaries, often referred to as "middlemen," in the distribution of healthcare benefits and medications. The bill seeks to ensure that beneficiaries receive the full value of their healthcare benefits without undue interference or profit-taking by these intermediaries.
While the specific text of the bill is not provided, the following key provisions are anticipated based on the title and intent:
Transparency Requirements: The bill may impose requirements on middlemen to disclose their fees and the financial arrangements they have with pharmaceutical companies and healthcare providers.
Direct Payment Models: It could promote direct payment models that allow beneficiaries to receive medications and services directly from providers, bypassing middlemen.
Regulatory Oversight: The legislation may establish or enhance regulatory oversight of middlemen to ensure compliance with new transparency standards.
Beneficiary Protections: Provisions may be included to protect beneficiaries from unexpected costs or delays in receiving necessary medications and services due to middlemen practices.
The following groups are likely to be impacted by the Protect Beneficiaries from Middlemen Act:
Healthcare Beneficiaries: Patients who rely on medications and healthcare services will benefit from increased transparency and potentially lower costs.
Pharmaceutical Companies: These companies may face new regulations regarding their pricing and distribution practices through middlemen.
Healthcare Providers: Providers may need to adjust their billing and payment practices in response to new regulations.
Middlemen (Pharmacy Benefit Managers, etc.): These entities will be directly affected by the new transparency and regulatory requirements, potentially altering their business models.
Referred Committees: Upon introduction, the bill was referred to the Committee on Energy and Commerce and the Committee on Ways and Means for consideration. The Speaker will determine the period for review by these committees.
Next Steps: The bill will undergo discussions and potential amendments within the committees before it can be brought to the floor for a vote.
The Protect Beneficiaries from Middlemen Act represents a significant step towards reforming the healthcare distribution system by targeting the role of middlemen. By promoting transparency and direct access to healthcare benefits, the bill aims to protect beneficiaries and ensure they receive the full value of their healthcare services. As the bill progresses through the legislative process, further details and specific provisions will be clarified.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
